Nad+ — reference
A central redox coenzyme, administered by IV infusion or injection in wellness settings on claims of energy and cellular repair.
Regulatory status
Not FDA-Approved. Not FDA-approved for any of the uses it is marketed for. IV NAD+ is compounded and administered outside an approved indication.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of Minutes in plasma (rapidly metabolized); IV infusion protocols exist because of this. Not a stable circulating molecule — 'half-life' is a less meaningful concept here than for a typical peptide.
This figure is tagged Limited data in our evidence system. The available data does not support a confident single figure, so this entry is flagged accordingly. Read any curve built from it as illustrative only. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Nad+ FDA-approved?
What is the half-life of Nad+?
How reliable is that half-life figure?
What cautions are associated with Nad+?
Does Peptide Plug publish dosing for Nad+?
Does Peptide Plug sell Nad+?
Related tools
Free, no account required.